At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Tenalisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Compassionate Use Study of Tenalisib (RP6530) in Patients Currently Receiving Treatment on Tenalisib Trials in Hematological Malignancies
In Brief
A Phase 2 clinical trial evaluating Tenalisib for Hematological Malignancies. Completed, enrolled 17 participants across 7 sites in 3 countries.
Detailed Summary
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesGeorgia, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionMar 2023
TodayJul 2026
First PostedOct 18, 2018
Enrollment StartNov 28, 2018
Primary CompletionMar 25, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 7.7 years ago
Interventions
Tenalisibdrug
BID Orally